Type 2 inflammation influences the severity of post-acute sequelae of SARS-CoV-2, highlighting the need for targeted interventions. Innovative therapies like ALIS, tezepelumab, and dupilumab show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results